

# Adenoid cystic carcinoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/A128A19741ACEN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A128A19741ACEN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Adenoid cystic carcinoma - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid cystic carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Adenoid cystic carcinoma Understanding

#### Adenoid cystic carcinoma: Overview

Adenoid cystic carcinoma (ACC) is a relatively rare form of cancer that most commonly develops in the salivary glands or other regions of the head and neck. ACC can occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, and various other areas. ACC tumors are characterized by a distinctive histological pattern of abnormal "nests" or cords of certain cells (epithelial cells) that surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes. Such characteristics are apparent during microscopic evaluation of tumor cells from a biopsy sample.

There are three histological tumor growth patterns common to ACC: cribriform, tubular, and solid. The cribriform growth pattern is most common and appears as a “Swiss cheese” pattern in histological stains. The exact cause of adenoid cystic carcinoma is unknown. However, current research suggests that genetic changes (mutations) are the underlying basis of cellular malignant transformation in many cancers, including ACC.

The diagnosis of adenoid cystic carcinoma is based upon a thorough clinical evaluation, characteristic symptoms and physical findings, a detailed patient history, and a variety of specialized tests. Such testing includes microscopic evaluation of tumor cells. Standard therapy includes surgical removal of the malignancy and affected tissue followed by radiation. If initial surgery is not an option due to the specific location and/or progression of the malignancy, therapy may include radiation alone. Radiation therapy preferentially destroys or injures rapidly dividing cells, primarily cancerous cells.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid cystic carcinoma R&D. The therapies under development are focused on novel approaches for Adenoid cystic carcinoma.

## Adenoid cystic carcinoma Emerging Drugs Chapters

This segment of the Adenoid cystic carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Adenoid cystic carcinoma Emerging Drugs

### Rivoceranib: Elevar Therapeutics

Rivoceranib is an oral anti-cancer compound being studied for its ability to fight solid cancers including late stage stomach cancer, colorectal cancer, liver cancer, and adenoid cystic carcinoma. Rivoceranib (Apatinib, YN968D1) is being developed outside

of China by Elevar Therapeutics, for the treatment of solid tumors including advanced or metastatic gastric cancer, colorectal cancer, hepatocellular carcinoma, and adenoid cystic carcinoma.

It is currently in Phase II stage of development for the treatment of Adenoid cystic carcinoma and is being developed by Elevar Therapeutics.

Further product details are provided in the report..

Adenoid cystic carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Adenoid cystic carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Adenoid cystic carcinoma

There are approx. 5+ key companies which are developing the Adenoid cystic carcinoma. The companies which have their Adenoid cystic carcinoma drug candidates in the most advanced stage, i.e. Phase II include, Elevar Therapeutics.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Adenoid cystic carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Adenoid cystic carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adenoid cystic carcinoma therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenoid cystic carcinoma drugs.

### Adenoid cystic carcinoma Report Insights

Adenoid cystic carcinoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Adenoid cystic carcinoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

## Unmet Needs

### Key Questions

#### Current Scenario and Emerging Therapies:

How many companies are developing Adenoid cystic carcinoma drugs?

How many Adenoid cystic carcinoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Adenoid cystic carcinoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenoid cystic carcinoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Adenoid cystic carcinoma and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Ayala Pharmaceuticals

CureVac

Elevar Therapeutics

Actuate Therapeutics

### Key Products

AL101

CV8102

Rivoceranib

9-ING-41

## Contents

Introduction

Executive Summary

Adenoid cystic carcinoma: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Adenoid cystic carcinoma– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Adenoid cystic carcinoma companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Adenoid cystic carcinoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Rivoceranib: Elevar Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis



**CV8102: CureVac**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

**Inactive Products**

Comparative Analysis

Adenoid cystic carcinoma Key Companies

Adenoid cystic carcinoma Key Products

Adenoid cystic carcinoma- Unmet Needs

Adenoid cystic carcinoma- Market Drivers and Barriers

Adenoid cystic carcinoma- Future Perspectives and Conclusion

Adenoid cystic carcinoma Analyst Views

Adenoid cystic carcinoma Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Adenoid cystic carcinoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Adenoid cystic carcinoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Adenoid cystic carcinoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A128A19741ACEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A128A19741ACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970